Pimozide added to clozapine for schizophrenia
About this title
Read the official source — NCT00158223Researchers compared Pimozide and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared Pimozide and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- New York and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 76
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00158223
- Official title
Show the full official title
Pimozide Augmentation of Clozapine in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
New York · W. Brentwood
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Pimozide and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Icahn School of Medicine at Mount Sinai, a university.
Did this study involve medication?
Yes. The study involved medication, including Pimozide and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
